Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 829M 725M 670M 626M 1.17B 78.38B 1.18B 7.97B 3.1B 38.54B 3.11B 3.05B 134B P/E 2026 *
14x
P/E 2027 * 10.7x
Enterprise Value 1.14B 996M 922M 860M 1.61B 108B 1.63B 10.95B 4.26B 52.97B 4.28B 4.19B 184B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.27x
Free-Float
50.3%
Yield 2026 *
-
Yield 2027 * -
1 day-2.55%
1 week-7.00%
Current month-2.76%
1 month-0.43%
3 months-4.68%
6 months-32.91%
Current year-31.55%
1 week 18.22
Extreme 18.22
20.4
1 month 17.73
Extreme 17.73
20.77
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
06-02Tax

Director

-769 0.0017%
06-01Free

Director

25,508 0.0579%
06-01Free

Director

25,508 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-7.00%-25.73%-68.60% 829M
+0.32%-2.41%+43.01%+140.80% 980B
+1.27%-1.85%+52.85%+39.65% 550B
+6.25%+3.80%+25.17%+67.39% 382B
-0.06%-3.09%+23.33%+16.78% 316B
+0.42%-1.28%+27.89%+14.71% 272B
+1.67%-1.47%+26.76%+32.88% 268B
+2.39%+4.42%-36.96%-45.12% 199B
+2.11%-1.66%+26.53%+50.10% 182B
+0.90%+0.46%+17.59%+59.86% 154B
Average +1.30%-3.27%+18.04%+30.84% 330.32B
Weighted average by Cap. +1.53%-3.51%+31.21%+64.45%

Financials

2026 *2027 *
Net sales 747M 653M 604M 563M 1.06B 70.57B 1.07B 7.17B 2.79B 34.7B 2.8B 2.74B 121B 788M 689M 637M 595M 1.12B 74.51B 1.12B 7.57B 2.95B 36.63B 2.96B 2.9B 127B
Net income 64M 55.92M 51.73M 48.28M 90.64M 6.05B 91.3M 615M 239M 2.97B 240M 235M 10.33B 84M 73.4M 67.89M 63.37M 119M 7.94B 120M 807M 314M 3.9B 315M 309M 13.56B
Net Debt 311M 272M 251M 234M 440M 29.37B 443M 2.98B 1.16B 14.44B 1.17B 1.14B 50.16B 173M 152M 140M 131M 246M 16.39B 247M 1.67B 648M 8.06B 651M 637M 27.99B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
23/06/26 18.33 $ -2.55% 767,365
18/06/26 18.81 $ -3.09% 1,327,603
17/06/26 19.41 $ -2.76% 1,008,517
16/06/26 19.96 $ +1.27% 724,208
15/06/26 19.71 $ -1.89% 528,512
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
18.81USD
Average target price
22.83USD
Spread / Average Target
+21.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!